Tag Archives: Jay Olson

Analyst Explains Why They Downgraded Their Rating on Mirati Therapeutics (MRTX)

Oppenheimer analyst Jay Olson downgraded Mirati Therapeutics (MRTX – Research Report) to Hold yesterday and set a price target of $160.00. The company’s shares closed last Friday at $156.62. According to TipRanks.com, Olson is a 3-star analyst with an average

Oppenheimer Gives a Buy Rating to Amgen (AMGN)

Oppenheimer analyst Jay Olson assigned a Buy rating to Amgen (AMGN – Research Report) yesterday and set a price target of $270.00. The company’s shares closed last Friday at $251.38. According to TipRanks.com, Olson is a 3-star analyst with an

Oppenheimer Issues a Buy Rating on 89bio (ETNB)

In a report released today, Jay Olson from Oppenheimer assigned a Buy rating to 89bio (ETNB – Research Report), with a price target of $60.00. The company’s shares closed last Wednesday at $23.78. According to TipRanks.com, Olson is a 4-star

Analysts Offer Insights on Healthcare Companies: Relmada Therapeutics (NASDAQ: RLMD) and Milestone Pharmaceuticals (NASDAQ: MIST)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Relmada Therapeutics (RLMD – Research Report) and Milestone Pharmaceuticals (MIST – Research Report) with bullish sentiments. Relmada Therapeutics (RLMD) Oppenheimer analyst Jay

Prothena (PRTA) Received its Third Buy in a Row

After Jefferies and H.C. Wainwright gave Prothena (NASDAQ: PRTA) a Buy rating last month, the company received another Buy, this time from Oppenheimer. Analyst Jay Olson maintained a Buy rating on Prothena today and set a price target of $35.00.

Prothena (PRTA) Gets a Buy Rating from Oppenheimer

Oppenheimer analyst Jay Olson assigned a Buy rating to Prothena (PRTA – Research Report) today and set a price target of $35.00. The company’s shares closed last Monday at $21.49. According to TipRanks.com, Olson is a 4-star analyst with an